INSILICO(03696.HK)

Price Range

Price Range

Overview

Last Updated:
  • Net Proceeds
    --
  • Margin Amount
    --
  • Margin Multiples
    unfilled
  • Expected Multiples
    unfilled

Margin Trend

Margin Multiples
Margin Amount (Billion)
longbridge loading
empty
no result found
Margin Multiples / Margin Amount

Brokerage Statistics

longbridge loading
empty
no result found
Company Encyclopedia
View More
name
INSILICO
03696.HK
Founded in 2014, we are a highly reputable AI-driven biotechnology company with a global presence.
News
View More

AI pharmaceutical company INSILICO starts its IPO today, raising up to HKD 2.3 billion

AI pharmaceutical company INSILICO today began its initial public offering, planning to issue a total of 94,690,500 shares globally, including 9,469,500 shares for public offering in Hong Kong and 85,221,000 shares for international offering. Based on an issue price of HKD 24.05 per share, it is expected to raise up to HKD 2.3 billion, with an IPO market capitalization reaching HKD 13.406 billion

Wallstreetcn·
HK
03696
0.00%
Wallstreetcn·
HK
03696
0.00%

InSilico Medicine Launches Hong Kong IPO

InSilico Medicine Launches Hong Kong IPO

marketscreener·
HK
03696
0.00%
marketscreener·
HK
03696
0.00%

Brief News: InSilico Medicine Cayman TopCo's Hong Kong Stock IPO has been filed with the China Securities Regulatory Commission

InSilico Medicine Cayman TopCo has received approval from Chinese securities regulators to list in Hong Kong, planning to sell up to 108 million shares. The company has previously applied for listing multiple times without success and applied again in November this year. In the first half of this year, InSilico Medicine reported a loss of $19.215 million, with revenue declining by 54% year-on-year. Its AI platform Pharma.AI has generated over 20 clinical or IND-stage assets, with a wide range of applications

BambooWorks·
HK
03696
0.00%
BambooWorks·
HK
03696
0.00%

Net profit soared by 110%! This CRO hidden champion can no longer be concealed

Chemexpress's net profit is expected to grow by 62.5% year-on-year in 2024, with the growth rate in the first half of the year soaring to 111.4%. The company's stock price has more than doubled in the past year, and it has reached a strategic cooperation agreement with Mabwell and InSilico Medicine Cayman TopCo to jointly develop a new ADC compound library. After experiencing an investment winter, the CRO industry is reshaping its ecosystem as the research and development of innovative drugs warms up

Wallstreetcn·
HK
03696
0.00%
SH
688131
+1.90%
SH
688062
-0.76%
Wallstreetcn·
HK
03696
0.00%
SH
688131
+1.90%
SH
688062
-0.76%

Guotai Junan Securities: A panoramic view of global AI pharmaceuticals from the perspective of three types of leaders in data, computing power, and models

Guojin Securities released a research report indicating that the AI pharmaceutical industry is about to achieve breakthroughs, with a preference for companies with rich pipelines and strong execution capabilities. With the development of AI technology, the first AI-driven developed drug is about to be approved for market launch. The report emphasizes that AI pharmaceuticals represent a new cross-disciplinary track in technology, and future leaders may be AI pharmaceutical companies, traditional pharmaceutical giants, or emerging technology firms. Multi-omics AI applications will significantly reduce costs, improve efficiency, and drive the rapid development of innovative drugs

Zhitong·
HK
03696
0.00%
US
NVDA
+3.93%
US
PFE
+0.60%
Zhitong·
HK
03696
0.00%
US
NVDA
+3.93%
US
PFE
+0.60%
Posts
View More

$INSILICO(03696.HK) first all in this, then top up $FOREST CABIN(02657.HK)

© 2025 Longbridge｜Disclaimer